Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the
breast. The lump or mass is usually painless, hard & irregular but
it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple
discharge, nipple retraction and presence of breast skin changes (eg
peau d' orange, nipple excoriation, scaling, inflammation, skin
tethering, ulceration, abscess).
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Priming with durvalumab 2 weeks before neoadjuvant chemotherapy (NACT) significantly improves pathological complete response (pCR) rates in patients with previously untreated early triple-negative breast cancer (TNBC), but only a numerical improvement is shown when the overall cohort of patients who received NACT with or without durvalumab is analyzed.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Breast cancer patients and their caregivers share similar perceptions of needs at diagnosis, according to a Singapore study. More patients consider family support while caregivers rate receiving prompt information on treatment and side-effects at time of diagnosis and early treatment as extremely important.
The histone deacetylase inhibitor tucidinostat, when used in combination with exemestane for treating patients with advanced, HR-positive, HER2-negative breast cancer, prolongs progression-free survival and substantially increases overall response and clinical benefit, while having a manageable safety profile, as shown in the results of the phase III ACE trial.
Annual breast cancer screening with magnetic resonance imaging (MRI) led to detection of fewer late-stage and node-positive cancers than annual mammography, according to the FaMRIsc* study from the Netherlands. However, specificity was lower and number of false-positives higher with MRI vs mammography.
The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The addition of radium-223 (Ra223) to enzalutamide for the treatment of mCRPC* was associated with increased fracture risk, which was entirely abolished with mandated use of bone-protecting agents (BPAs) such as zoledronic acid and denosumab, according to interim results of the EORTC 1333 (PEACE III) trial.